Pledge to reduce antipsychotic use in dementia sufferers

NewsGuard 100/100 Score

A new coalition of 44 organizations called the Dementia Action Alliance, has called for a cut in the use of anti-psychotic drugs for patients with dementia. The coalition includes Alzheimer's Research Trust, Alzheimer's Society, BUPA, Dementia UK, the Royal College of Psychiatrists, Royal College of General Practitioners and Stroke Association.

A Government-commissioned review found that nearly 145,000 people with dementia are being wrongly prescribed powerful anti-psychotic medication. These drugs given to curb aggression, agitation, shouting and sleep disturbances kill nearly 1,800 each year. Research shows that people taking them are three times as likely to have a stroke and they are more likely to go into long-term decline.

According to Ruth Sutherland, interim chief executive of the Alzheimer's Society, this alliance provided an “unprecedented opportunity to bring about real change for people with dementia”. She said, “Putting dementia on the map in such a way will not only transform lives but also has the potential to save millions of pounds…There are 750,000 people living with dementia in the UK and this costs the country £20 billion a year. It is without doubt the health and social crisis of this generation so this joint approach cannot come soon enough.”

Care Services Minister Paul Burstow also added, “Dementia is more than a health issue, it's one of the defining social challenges of our time. We have to prepare ourselves now for the impact this will have on our society as our population ages…This Dementia Declaration shows tremendous commitment from across health and care services and the voluntary sector, to transform services and tackle stigma to make a difference for people with dementia and their families. Willingness to join forces to act should spur more organizations to join this movement for change.”

The declaration of the alliance has seven aims, including the reduction in the use of anti-psychotics and patients having more control over decisions, being part of a community and living in an enabling and supportive environment.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Pledge to reduce antipsychotic use in dementia sufferers. News-Medical. Retrieved on May 01, 2024 from https://www.news-medical.net/news/20101026/Pledge-to-reduce-antipsychotic-use-in-dementia-sufferers.aspx.

  • MLA

    Mandal, Ananya. "Pledge to reduce antipsychotic use in dementia sufferers". News-Medical. 01 May 2024. <https://www.news-medical.net/news/20101026/Pledge-to-reduce-antipsychotic-use-in-dementia-sufferers.aspx>.

  • Chicago

    Mandal, Ananya. "Pledge to reduce antipsychotic use in dementia sufferers". News-Medical. https://www.news-medical.net/news/20101026/Pledge-to-reduce-antipsychotic-use-in-dementia-sufferers.aspx. (accessed May 01, 2024).

  • Harvard

    Mandal, Ananya. 2018. Pledge to reduce antipsychotic use in dementia sufferers. News-Medical, viewed 01 May 2024, https://www.news-medical.net/news/20101026/Pledge-to-reduce-antipsychotic-use-in-dementia-sufferers.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Smartphone app shows promise in detecting early signs of frontotemporal dementia